Physician profile
Robert Whipple
NPI 1427073824
$1,450.15
in general payments reported to CMS, 2019-2025
24 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $275 · 2021: $270 · 2022: $420 · 2023: $70.43 · 2024: $15.75 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $214.84 | 2019-2022 | |
| Sk Life Science, INC. | $152.44 | 2025 | |
| Novo Nordisk INC | $129.30 | 2019-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $118.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $115.88 | 2019-2022 | |
| Astellas Pharma US INC | $110.90 | 2019-2023 | Myrbetriq |
| Abbvie INC. | $75.23 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.79 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $59.47 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $53.80 | 2022 | |
| Eisai INC. | $53.28 | 2020-2021 | |
| Abbott Laboratories | $43.70 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $38.64 | 2021 | |
| Amgen INC. | $35.23 | 2021 | |
| Lilly USA, LLC | $24.38 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $24.16 | 2021-2022 | |
| Horizon Therapeutics Plc | $20.99 | 2022 | |
| Biosense Webster, INC. | $18.14 | 2021 | |
| Intra-Sana Laboratories | $16.91 | 2021 | |
| Dexcom, INC. | $14.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.83 | 2019 | |
| Allergan, INC. | $14.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.44 | 2021 | |
| Amarin Pharma, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Whipple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.